168 related articles for article (PubMed ID: 14609622)
1. Cardiovascular effects of tadalafil.
Kloner RA; Mitchell M; Emmick JT
Am J Cardiol; 2003 Nov; 92(9A):37M-46M. PubMed ID: 14609622
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.
Kloner RA; Mitchell M; Emmick JT
Am J Cardiol; 2003 Nov; 92(9A):47M-57M. PubMed ID: 14609623
[TBL] [Abstract][Full Text] [Related]
3. Roundtable discussion: tadalafil study group.
Kloner RA; Brindis RG; Cheitlin MD; Kuritzky L; Miller TA; Padma-Nathan H; Rosen RC
Am J Cardiol; 2003 Nov; 92(9A):58M-65M. PubMed ID: 14609624
[No Abstract] [Full Text] [Related]
4. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina.
Webb DJ; Muirhead GJ; Wulff M; Sutton JA; Levi R; Dinsmore WW
J Am Coll Cardiol; 2000 Jul; 36(1):25-31. PubMed ID: 10898408
[TBL] [Abstract][Full Text] [Related]
5. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.
Kloner RA; Jackson G; Emmick JT; Mitchell MI; Bedding A; Warner MR; Pereira A
J Urol; 2004 Nov; 172(5 Pt 1):1935-40. PubMed ID: 15540759
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
7. Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men.
MacDiarmid SA; Hill LA; Volinn W; Hoel G
Urology; 2010 Mar; 75(3):520-5. PubMed ID: 20080287
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects.
Giuliano F; Kaplan SA; Cabanis MJ; Astruc B
Urology; 2006 Jun; 67(6):1199-204. PubMed ID: 16765179
[TBL] [Abstract][Full Text] [Related]
9. Time course of the interaction between tadalafil and nitrates.
Kloner RA; Hutter AM; Emmick JT; Mitchell MI; Denne J; Jackson G
J Am Coll Cardiol; 2003 Nov; 42(10):1855-60. PubMed ID: 14642699
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
Broderick GA; Donatucci CF; Hatzichristou D; Torres LO; Valiquette L; Zhao Y; Loughney K; Sides GD; Ahuja S
J Sex Med; 2006 Jul; 3(4):668-675. PubMed ID: 16839323
[TBL] [Abstract][Full Text] [Related]
11. Overall cardiovascular profile of sildenafil citrate.
Zusman RM; Morales A; Glasser DB; Osterloh IH
Am J Cardiol; 1999 Mar; 83(5A):35C-44C. PubMed ID: 10078541
[TBL] [Abstract][Full Text] [Related]
12. Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
Park JW; Leithäuser B; Jung F
Clin Hemorheol Microcirc; 2008; 39(1-4):323-8. PubMed ID: 18503141
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.
Webb DJ; Freestone S; Allen MJ; Muirhead GJ
Am J Cardiol; 1999 Mar; 83(5A):21C-28C. PubMed ID: 10078539
[TBL] [Abstract][Full Text] [Related]
14. Sildenafil in patients with cardiovascular disease.
Brindis RG; Kloner RA
Am J Cardiol; 2003 Nov; 92(9A):26M-36M. PubMed ID: 14609621
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects.
Guillaume M; Lonsdale F; Darstein C; Jimenez MC; Mitchell MI
J Clin Pharmacol; 2007 Oct; 47(10):1303-10. PubMed ID: 17906163
[TBL] [Abstract][Full Text] [Related]
16. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.
Young JM; Feldman RA; Auerbach SM; Kaufman JM; Garcia CS; Shen W; Murphy AM; Beasley CM; Hague JA; Ahuja S
J Androl; 2005; 26(3):310-8. PubMed ID: 15866997
[TBL] [Abstract][Full Text] [Related]
17. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events.
Jackson G; Kloner RA; Costigan TM; Warner MR; Emmick JT
J Sex Med; 2004 Sep; 1(2):161-7. PubMed ID: 16422970
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.
Conti CR; Pepine CJ; Sweeney M
Am J Cardiol; 1999 Mar; 83(5A):29C-34C. PubMed ID: 10078540
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective.
Jackson G; Montorsi P; Cheitlin MD
Urology; 2006 Sep; 68(3 Suppl):47-60. PubMed ID: 17011375
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of sildenafil citrate and recommendations for its use.
Kloner RA; Zusman RM
Am J Cardiol; 1999 Sep; 84(5B):11N-17N. PubMed ID: 10503571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
